Exosomes in transplantation: Role in allograft rejection, diagnostic biomarker, and therapeutic potential
Exosomes are 50–200 nm-sized extracellular vesicles that are secreted by cells to transfer signals and communicate with other cells. Recent research has revealed that allograft-specific exosomes containing proteins, lipids, and genetic materials are released into circulation post-transplantation whi...
Gespeichert in:
Veröffentlicht in: | Life sciences (1973) 2023-07, Vol.324, p.121722-121722, Article 121722 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 121722 |
---|---|
container_issue | |
container_start_page | 121722 |
container_title | Life sciences (1973) |
container_volume | 324 |
creator | Saravanan, Prathab Balaji Kalivarathan, Jagan Khan, Faizaan Shah, Rashi Levy, Marlon F. Kanak, Mazhar A. |
description | Exosomes are 50–200 nm-sized extracellular vesicles that are secreted by cells to transfer signals and communicate with other cells. Recent research has revealed that allograft-specific exosomes containing proteins, lipids, and genetic materials are released into circulation post-transplantation which are powerful indicators of graft failure in solid-organ and tissue transplantations. The macromolecular content of exosomes released by the allograft and the immune cells serve as potential biomarkers for assessing the function and the acceptance/rejection status of the transplanted grafts. Identifying these biomarkers could aid in the development of therapeutic strategies to improve graft longevity. Exosomes can be used to deliver therapeutic agonists/antagonists to grafts and prevent rejection. Inducing long-term graft tolerance has been demonstrated in many studies using exosomes from immunomodulatory cells such as immature DCs, T regulatory cells, and MSCs. The use of graft-specific exosomes for targeted drug therapy has the potential to reduce the unwanted side effects of immunosuppressive drugs. Overall, in this review, we have explored the critical role of exosomes in the recognition and cross-presentation of donor organ-specific antigens during allograft rejection. Additionally, we have discussed the potential of exosomes as a biomarker for monitoring graft function and damage, as well as their potential therapeutic applications in mitigating allograft rejection.
Allograft exosomal contents secreted to the recipient's circulation: Contents of exosomes include a complex of various membrane proteins like tetraspanins (CD9, CD63, CD81, etc); immunoregulatory proteins (MHC, HLA, GAD, etc); Lipid rafts (Sphingomyelin, cholesterol, ceramide, etc); various small RNAs (microRNA, lncRNA, siRNA, etc); messenger RNAs; Chaperons (HSP 70, HSP 90, HSP 105, etc); ESCRT complex proteins; damage-associated molecular patterns (Histones, HMGB1, etc); cytoskeletal proteins (actin, keratin, vimentin, etc); cytokines (TNF, IL1B, IL6, etc). [Display omitted] |
doi_str_mv | 10.1016/j.lfs.2023.121722 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2806995028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0024320523003569</els_id><sourcerecordid>2806995028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-fe68ac0e39f2825dc8a9754000854633cf5d131b798a2b676e1c1c8392b45cbc3</originalsourceid><addsrcrecordid>eNp9kLtOwzAUhi0EoqXwACwoI0NTfKkTByZUlYtUCQnBbDnOSXFJ42A7CN4eRy2MTGf4Lzr_h9A5wTOCSXa1mTW1n1FM2YxQklN6gMZE5EWKM0YO0RhjOk8ZxXyETrzfYIw5z9kxGrGcYMzyYozM8st6uwWfmDYJTrW-a1QbVDC2vU6ebQODoJrGrp2qQ-JgA3oQp0ll1Lq1PhidlMZulXsHN01UWyXhDZzqoB-kzgZog1HNKTqqVePhbH8n6PVu-bJ4SFdP94-L21WqGWchrSETSmNgRU0F5ZUWqsj5PP4u-DxjTNe8IoyUeSEULbM8A6KJFqyg5ZzrUrMJutz1ds5-9OCD3BqvoYmzwPZeUoGzouCYimglO6t21nsHteyciUO-JcFyICw3MhKWA2G5IxwzF_v6vtxC9Zf4RRoNNzsDxJGfBpz02kCroTIuopOVNf_U_wDDXozG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2806995028</pqid></control><display><type>article</type><title>Exosomes in transplantation: Role in allograft rejection, diagnostic biomarker, and therapeutic potential</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Saravanan, Prathab Balaji ; Kalivarathan, Jagan ; Khan, Faizaan ; Shah, Rashi ; Levy, Marlon F. ; Kanak, Mazhar A.</creator><creatorcontrib>Saravanan, Prathab Balaji ; Kalivarathan, Jagan ; Khan, Faizaan ; Shah, Rashi ; Levy, Marlon F. ; Kanak, Mazhar A.</creatorcontrib><description>Exosomes are 50–200 nm-sized extracellular vesicles that are secreted by cells to transfer signals and communicate with other cells. Recent research has revealed that allograft-specific exosomes containing proteins, lipids, and genetic materials are released into circulation post-transplantation which are powerful indicators of graft failure in solid-organ and tissue transplantations. The macromolecular content of exosomes released by the allograft and the immune cells serve as potential biomarkers for assessing the function and the acceptance/rejection status of the transplanted grafts. Identifying these biomarkers could aid in the development of therapeutic strategies to improve graft longevity. Exosomes can be used to deliver therapeutic agonists/antagonists to grafts and prevent rejection. Inducing long-term graft tolerance has been demonstrated in many studies using exosomes from immunomodulatory cells such as immature DCs, T regulatory cells, and MSCs. The use of graft-specific exosomes for targeted drug therapy has the potential to reduce the unwanted side effects of immunosuppressive drugs. Overall, in this review, we have explored the critical role of exosomes in the recognition and cross-presentation of donor organ-specific antigens during allograft rejection. Additionally, we have discussed the potential of exosomes as a biomarker for monitoring graft function and damage, as well as their potential therapeutic applications in mitigating allograft rejection.
Allograft exosomal contents secreted to the recipient's circulation: Contents of exosomes include a complex of various membrane proteins like tetraspanins (CD9, CD63, CD81, etc); immunoregulatory proteins (MHC, HLA, GAD, etc); Lipid rafts (Sphingomyelin, cholesterol, ceramide, etc); various small RNAs (microRNA, lncRNA, siRNA, etc); messenger RNAs; Chaperons (HSP 70, HSP 90, HSP 105, etc); ESCRT complex proteins; damage-associated molecular patterns (Histones, HMGB1, etc); cytoskeletal proteins (actin, keratin, vimentin, etc); cytokines (TNF, IL1B, IL6, etc). [Display omitted]</description><identifier>ISSN: 0024-3205</identifier><identifier>EISSN: 1879-0631</identifier><identifier>DOI: 10.1016/j.lfs.2023.121722</identifier><identifier>PMID: 37100379</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Allografts ; APC Chimerism ; APC Cross-presentation ; Biomarker ; Biomarkers - metabolism ; Exosome biogenesis ; Exosomes ; Exosomes - metabolism ; Graft rejection ; Graft Rejection - prevention & control ; Graft tolerance ; Heart ; Islets ; Kidney ; Liver ; Lungs ; miRNA ; Transplantation ; Transplantation, Homologous</subject><ispartof>Life sciences (1973), 2023-07, Vol.324, p.121722-121722, Article 121722</ispartof><rights>2023 Elsevier Inc.</rights><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-fe68ac0e39f2825dc8a9754000854633cf5d131b798a2b676e1c1c8392b45cbc3</citedby><cites>FETCH-LOGICAL-c353t-fe68ac0e39f2825dc8a9754000854633cf5d131b798a2b676e1c1c8392b45cbc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lfs.2023.121722$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37100379$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saravanan, Prathab Balaji</creatorcontrib><creatorcontrib>Kalivarathan, Jagan</creatorcontrib><creatorcontrib>Khan, Faizaan</creatorcontrib><creatorcontrib>Shah, Rashi</creatorcontrib><creatorcontrib>Levy, Marlon F.</creatorcontrib><creatorcontrib>Kanak, Mazhar A.</creatorcontrib><title>Exosomes in transplantation: Role in allograft rejection, diagnostic biomarker, and therapeutic potential</title><title>Life sciences (1973)</title><addtitle>Life Sci</addtitle><description>Exosomes are 50–200 nm-sized extracellular vesicles that are secreted by cells to transfer signals and communicate with other cells. Recent research has revealed that allograft-specific exosomes containing proteins, lipids, and genetic materials are released into circulation post-transplantation which are powerful indicators of graft failure in solid-organ and tissue transplantations. The macromolecular content of exosomes released by the allograft and the immune cells serve as potential biomarkers for assessing the function and the acceptance/rejection status of the transplanted grafts. Identifying these biomarkers could aid in the development of therapeutic strategies to improve graft longevity. Exosomes can be used to deliver therapeutic agonists/antagonists to grafts and prevent rejection. Inducing long-term graft tolerance has been demonstrated in many studies using exosomes from immunomodulatory cells such as immature DCs, T regulatory cells, and MSCs. The use of graft-specific exosomes for targeted drug therapy has the potential to reduce the unwanted side effects of immunosuppressive drugs. Overall, in this review, we have explored the critical role of exosomes in the recognition and cross-presentation of donor organ-specific antigens during allograft rejection. Additionally, we have discussed the potential of exosomes as a biomarker for monitoring graft function and damage, as well as their potential therapeutic applications in mitigating allograft rejection.
Allograft exosomal contents secreted to the recipient's circulation: Contents of exosomes include a complex of various membrane proteins like tetraspanins (CD9, CD63, CD81, etc); immunoregulatory proteins (MHC, HLA, GAD, etc); Lipid rafts (Sphingomyelin, cholesterol, ceramide, etc); various small RNAs (microRNA, lncRNA, siRNA, etc); messenger RNAs; Chaperons (HSP 70, HSP 90, HSP 105, etc); ESCRT complex proteins; damage-associated molecular patterns (Histones, HMGB1, etc); cytoskeletal proteins (actin, keratin, vimentin, etc); cytokines (TNF, IL1B, IL6, etc). [Display omitted]</description><subject>Allografts</subject><subject>APC Chimerism</subject><subject>APC Cross-presentation</subject><subject>Biomarker</subject><subject>Biomarkers - metabolism</subject><subject>Exosome biogenesis</subject><subject>Exosomes</subject><subject>Exosomes - metabolism</subject><subject>Graft rejection</subject><subject>Graft Rejection - prevention & control</subject><subject>Graft tolerance</subject><subject>Heart</subject><subject>Islets</subject><subject>Kidney</subject><subject>Liver</subject><subject>Lungs</subject><subject>miRNA</subject><subject>Transplantation</subject><subject>Transplantation, Homologous</subject><issn>0024-3205</issn><issn>1879-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kLtOwzAUhi0EoqXwACwoI0NTfKkTByZUlYtUCQnBbDnOSXFJ42A7CN4eRy2MTGf4Lzr_h9A5wTOCSXa1mTW1n1FM2YxQklN6gMZE5EWKM0YO0RhjOk8ZxXyETrzfYIw5z9kxGrGcYMzyYozM8st6uwWfmDYJTrW-a1QbVDC2vU6ebQODoJrGrp2qQ-JgA3oQp0ll1Lq1PhidlMZulXsHN01UWyXhDZzqoB-kzgZog1HNKTqqVePhbH8n6PVu-bJ4SFdP94-L21WqGWchrSETSmNgRU0F5ZUWqsj5PP4u-DxjTNe8IoyUeSEULbM8A6KJFqyg5ZzrUrMJutz1ds5-9OCD3BqvoYmzwPZeUoGzouCYimglO6t21nsHteyciUO-JcFyICw3MhKWA2G5IxwzF_v6vtxC9Zf4RRoNNzsDxJGfBpz02kCroTIuopOVNf_U_wDDXozG</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Saravanan, Prathab Balaji</creator><creator>Kalivarathan, Jagan</creator><creator>Khan, Faizaan</creator><creator>Shah, Rashi</creator><creator>Levy, Marlon F.</creator><creator>Kanak, Mazhar A.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20230701</creationdate><title>Exosomes in transplantation: Role in allograft rejection, diagnostic biomarker, and therapeutic potential</title><author>Saravanan, Prathab Balaji ; Kalivarathan, Jagan ; Khan, Faizaan ; Shah, Rashi ; Levy, Marlon F. ; Kanak, Mazhar A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-fe68ac0e39f2825dc8a9754000854633cf5d131b798a2b676e1c1c8392b45cbc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Allografts</topic><topic>APC Chimerism</topic><topic>APC Cross-presentation</topic><topic>Biomarker</topic><topic>Biomarkers - metabolism</topic><topic>Exosome biogenesis</topic><topic>Exosomes</topic><topic>Exosomes - metabolism</topic><topic>Graft rejection</topic><topic>Graft Rejection - prevention & control</topic><topic>Graft tolerance</topic><topic>Heart</topic><topic>Islets</topic><topic>Kidney</topic><topic>Liver</topic><topic>Lungs</topic><topic>miRNA</topic><topic>Transplantation</topic><topic>Transplantation, Homologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saravanan, Prathab Balaji</creatorcontrib><creatorcontrib>Kalivarathan, Jagan</creatorcontrib><creatorcontrib>Khan, Faizaan</creatorcontrib><creatorcontrib>Shah, Rashi</creatorcontrib><creatorcontrib>Levy, Marlon F.</creatorcontrib><creatorcontrib>Kanak, Mazhar A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Life sciences (1973)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saravanan, Prathab Balaji</au><au>Kalivarathan, Jagan</au><au>Khan, Faizaan</au><au>Shah, Rashi</au><au>Levy, Marlon F.</au><au>Kanak, Mazhar A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exosomes in transplantation: Role in allograft rejection, diagnostic biomarker, and therapeutic potential</atitle><jtitle>Life sciences (1973)</jtitle><addtitle>Life Sci</addtitle><date>2023-07-01</date><risdate>2023</risdate><volume>324</volume><spage>121722</spage><epage>121722</epage><pages>121722-121722</pages><artnum>121722</artnum><issn>0024-3205</issn><eissn>1879-0631</eissn><abstract>Exosomes are 50–200 nm-sized extracellular vesicles that are secreted by cells to transfer signals and communicate with other cells. Recent research has revealed that allograft-specific exosomes containing proteins, lipids, and genetic materials are released into circulation post-transplantation which are powerful indicators of graft failure in solid-organ and tissue transplantations. The macromolecular content of exosomes released by the allograft and the immune cells serve as potential biomarkers for assessing the function and the acceptance/rejection status of the transplanted grafts. Identifying these biomarkers could aid in the development of therapeutic strategies to improve graft longevity. Exosomes can be used to deliver therapeutic agonists/antagonists to grafts and prevent rejection. Inducing long-term graft tolerance has been demonstrated in many studies using exosomes from immunomodulatory cells such as immature DCs, T regulatory cells, and MSCs. The use of graft-specific exosomes for targeted drug therapy has the potential to reduce the unwanted side effects of immunosuppressive drugs. Overall, in this review, we have explored the critical role of exosomes in the recognition and cross-presentation of donor organ-specific antigens during allograft rejection. Additionally, we have discussed the potential of exosomes as a biomarker for monitoring graft function and damage, as well as their potential therapeutic applications in mitigating allograft rejection.
Allograft exosomal contents secreted to the recipient's circulation: Contents of exosomes include a complex of various membrane proteins like tetraspanins (CD9, CD63, CD81, etc); immunoregulatory proteins (MHC, HLA, GAD, etc); Lipid rafts (Sphingomyelin, cholesterol, ceramide, etc); various small RNAs (microRNA, lncRNA, siRNA, etc); messenger RNAs; Chaperons (HSP 70, HSP 90, HSP 105, etc); ESCRT complex proteins; damage-associated molecular patterns (Histones, HMGB1, etc); cytoskeletal proteins (actin, keratin, vimentin, etc); cytokines (TNF, IL1B, IL6, etc). [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>37100379</pmid><doi>10.1016/j.lfs.2023.121722</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0024-3205 |
ispartof | Life sciences (1973), 2023-07, Vol.324, p.121722-121722, Article 121722 |
issn | 0024-3205 1879-0631 |
language | eng |
recordid | cdi_proquest_miscellaneous_2806995028 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Allografts APC Chimerism APC Cross-presentation Biomarker Biomarkers - metabolism Exosome biogenesis Exosomes Exosomes - metabolism Graft rejection Graft Rejection - prevention & control Graft tolerance Heart Islets Kidney Liver Lungs miRNA Transplantation Transplantation, Homologous |
title | Exosomes in transplantation: Role in allograft rejection, diagnostic biomarker, and therapeutic potential |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A54%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exosomes%20in%20transplantation:%20Role%20in%20allograft%20rejection,%20diagnostic%20biomarker,%20and%20therapeutic%20potential&rft.jtitle=Life%20sciences%20(1973)&rft.au=Saravanan,%20Prathab%20Balaji&rft.date=2023-07-01&rft.volume=324&rft.spage=121722&rft.epage=121722&rft.pages=121722-121722&rft.artnum=121722&rft.issn=0024-3205&rft.eissn=1879-0631&rft_id=info:doi/10.1016/j.lfs.2023.121722&rft_dat=%3Cproquest_cross%3E2806995028%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2806995028&rft_id=info:pmid/37100379&rft_els_id=S0024320523003569&rfr_iscdi=true |